Mikart, LLC, a US-based Contract Development and Manufacturing Organisation (CDMO), announced on Thursday that it has added Fette double-sided tablet presses to increase its production capacity and meet the product demands of its increasing number of customers.
The tablet presses have advanced features, which include automatic weight control, metal detectors, dedusters and bulk powder feeding systems for optimal efficiency and precision of tablet production applications.
Michael Kallelis, Mikart, LLC CEO, said, 'We are thrilled to expand our Fette tablet press platforms into our manufacturing operations. These high-speed and high-volume presses mark a significant milestone in our journey towards enhancing client satisfaction and accommodating the growing brand and generic market.'
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical
Veeda Group rebrands as 'Veeda Lifesciences'
ANI Pharmaceuticals launches generic Motegrity tablets
Hikma Pharmaceuticals USA receives FDA approval for diabetes drug
Full Circles Therapeutics advances non-viral gene editing innovation
Induction Healthcare secures national video solution contract in Ireland